Teva Canada launches generic Avelox

TORONTO — Teva Canada on Tuesday announced the launch of its generic Avelox (moxifloxacin) tablets following Health Canada approval. The drug is intended to treat respiratory tract infections, including mild to moderate pneuomonia, acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis. 

 

“As cold and flu season is just beginning, we are proud to have played our part in expediting the availability of a more affordable version of this physician and pharmacist trusted medication for respiratory tract infections," Teva Canada’s SVP and general manager Doug Sommerville said. 

 

Avelox had sales of $28.4 million as of September 2015, according to data from IMS Brogan.